195 related articles for article (PubMed ID: 20178698)
1. Psoriasis: can statins play a dual role?
Rajpara AN; Goldner R; Gaspari A
Dermatol Online J; 2010 Feb; 16(2):2. PubMed ID: 20178698
[TBL] [Abstract][Full Text] [Related]
2. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Späh F
Br J Dermatol; 2008 Aug; 159 Suppl 2():10-7. PubMed ID: 18700910
[TBL] [Abstract][Full Text] [Related]
3. Should we screen asymptomatic individuals for coronary artery disease or implement universal lipid-lowering therapy?
Thomas GS
Cardiol Rev; 2005; 13(1):40-5. PubMed ID: 15596028
[TBL] [Abstract][Full Text] [Related]
4. API expert consensus document on management of ischemic heart disease.
Association of Physicians of India
J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
6. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
7. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
Motz W
MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
[No Abstract] [Full Text] [Related]
8. Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property.
Li JJ; Zheng X; Li J
Med Hypotheses; 2007; 69(2):333-7. PubMed ID: 17215087
[TBL] [Abstract][Full Text] [Related]
9. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.
Klingenberg R; Hansson GK
Eur Heart J; 2009 Dec; 30(23):2838-44. PubMed ID: 19880848
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
Wilensky RL; Hamamdzic D
Curr Opin Cardiol; 2007 Nov; 22(6):545-51. PubMed ID: 17921743
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hyperlipidemia in cardiac transplant recipients.
Bilchick KC; Henrikson CA; Skojec D; Kasper EK; Blumenthal RS
Am Heart J; 2004 Aug; 148(2):200-10. PubMed ID: 15308989
[TBL] [Abstract][Full Text] [Related]
12. Incidence of new stroke or new myocardial infarction or death in patients with severe carotid arterial disease treated with and without statins.
Ravipati G; Aronow WS; Ahn C; Channamsetty V; Sekhri V
Am J Cardiol; 2006 Nov; 98(9):1170-1. PubMed ID: 17056320
[TBL] [Abstract][Full Text] [Related]
13. Cellular and molecular mechanisms of statins: an update on pleiotropic effects.
Satoh M; Takahashi Y; Tabuchi T; Minami Y; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M
Clin Sci (Lond); 2015 Jul; 129(2):93-105. PubMed ID: 25927679
[TBL] [Abstract][Full Text] [Related]
14. Common community infections and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1.
Nikolopoulou A; Tousoulis D; Antoniades C; Petroheilou K; Vasiliadou C; Papageorgiou N; Koniari K; Stefanadi E; Latsios G; Siasos G; Stefanadis C
Int J Cardiol; 2008 Nov; 130(2):246-50. PubMed ID: 18063147
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein: risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?
Koenig W
Ital Heart J; 2001 Mar; 2(3):157-63. PubMed ID: 11305526
[TBL] [Abstract][Full Text] [Related]
16. [Hyperlipidemia: decreasing lipid values and effects of statins].
Mathes P
Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
[No Abstract] [Full Text] [Related]
17. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
Koenig W
Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
[TBL] [Abstract][Full Text] [Related]
18. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.
Coppola G; Novo S
Arch Med Res; 2007 Jul; 38(5):479-88. PubMed ID: 17560452
[TBL] [Abstract][Full Text] [Related]
19. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
Baber U; Toto RD; de Lemos JA
Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281
[TBL] [Abstract][Full Text] [Related]
20. Detection of increased temperature of the culprit lesion after recent myocardial infarction: the favorable effect of statins.
Toutouzas K; Vaina S; Tsiamis E; Vavuranakis M; Mitropoulos J; Bosinakou E; Toutouzas P; Stefanadis C
Am Heart J; 2004 Nov; 148(5):783-8. PubMed ID: 15523307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
